Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 20;6(1):00311-2019.
doi: 10.1183/23120541.00311-2019. eCollection 2020 Jan.

Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis

Brian D Kent  1   2 , Grainne d'Ancona  1   2 , Mariana Fernandes  1 , Linda Green  1 , Cris Roxas  1 , Louise Thomson  1 , Alexandra M Nanzer  1   2 , Joanne Kavanagh  1 , Sangita Agarwal  3 , David J Jackson  1   2
Affiliations

Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis

Brian D Kent et al. ERJ Open Res. .

Abstract

Blockade of interleukin-5 with reslizumab appears to have significant oral corticosteroid sparing effects in patients with eosinophilic granulomatosis with polyangiitis and severe eosinophilic asthma http://bit.ly/2D2yYSK.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: B.D. Kent reports an educational travel grant from Teva Pharmaceuticals during the conduct of the study. Conflict of interest: G. d'Ancona reports an educational travel grant and speaker fees from Teva Pharmaceuticals during the conduct of the study. Conflict of interest: M. Fernandes has nothing to disclose. Conflict of interest: L. Green has nothing to disclose. Conflict of interest: C. Roxas has nothing to disclose. Conflict of interest: L. Thomson has nothing to disclose. Conflict of interest: A.M. Nanzer reports speaker fees from Teva Pharmaceuticals during the conduct of the study. Conflict of interest: J. Kavanagh has nothing to disclose. Conflict of interest: S. Agarwal reports grants and personal fees from Teva Pharmaceuticals, during the conduct of the study. Conflict of interest: D.J. Jackson reports and educational travel grant and speaker fees from Teva Pharmaceuticals during the conduct of the study.

Figures

FIGURE 1
FIGURE 1
Changes in a) oral corticosteroid (OCS) dose (p<0.001), b) mini-Asthma Quality of Life Questionnaire (mini-AQLQ) score (p=0.001) and c) seven-item Asthma Control Questionnaire (ACQ7) score (p=0.081) following 48 weeks of treatment with reslizumab. Data are presented as mean±sd.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Comarmond C, Pagnoux C, Khellaf M, et al. . Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 2013; 65: 270–281. doi:10.1002/art.37721 - DOI - PubMed
    1. Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol 2014; 10: 474–483. doi:10.1038/nrrheum.2014.98 - DOI - PMC - PubMed
    1. Groh M, Pagnoux C, Baldini C, et al. . Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015; 26: 545–553. doi:10.1016/j.ejim.2015.04.022 - DOI - PubMed
    1. Ribi C, Cohen P, Pagnoux C, et al. . Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58: 586–594. doi:10.1002/art.23198 - DOI - PubMed
    1. Cottin V, Bel E, Bottero P, et al. . Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss). Eur Respir J 2016; 48: 1429–1441. doi:10.1183/13993003.00097-2016 - DOI - PubMed

LinkOut - more resources